Circulating CCL5 Levels in Patients with Breast Cancer: Is There a Correlation with Lymph Node Metastasis?

Table 2

Association between plasma CCL5 levels (ng/mL) and tumour characteristics.

Variable	Statistics
	𝑁	Mean ± SD	Median	Range	𝑃 value
CCL5 plasma
pN	238	81,37 ± 34,68	78,16	1,72–208,12
0	123	79,13 ± 33,87	73,40	5,76–194,20	0.215
1	56	83,27 ± 37,01	84,22	1,72–189,28
2/3	32	88,34 ± 33,19	89,70	25,32–208,12
CCL5 plasma
pT	238	81,37 ± 34,68	78,16	1,72–208,12
1	87	76,16 ± 33,27	73,40	1,72–178,00	0.068
2	107	83,22 ± 32,80	84,11	23,29–189,28
3/4	15	104,06 ± 47,52	96,86	43,89–208,12
CCL5 plasma
LVI	238	81,37 ± 34,68	78,16	1,72–208,12
No	151	79,24 ± 35,21	74,24	1,72–194,20	0.087
Yes	72	87,00 ± 35,26	83,62	10,93–208,12
CCL5 plasma
Multifocal	238	81,37 ± 34,68	78,16	1,723–208,12
No	194	80,36 ± 35,52	77,48	1,723–208,12	0.364
Yes	41	85,14 ± 31,39	78,48	24,85–178,00

𝑃 values are based on a Kruskal Wallis test (no. of levels > 2).
Min: the lowest value, max: the highest value, Q1: percentile 25, Q3: percentile 75, SD: standard deviation.